肝细胞癌降期后肝移植(XXL):随机对照2b/3期试验
XXL试验纳入74例超米兰标准、无大血管侵犯或肝外转移、肝功能Child-Pugh A-B7的肝细胞癌患者,经局部/手术/系统治疗降期后,45例部分或完全缓解者随机接受肝移植或非移植治疗。
要点
- 试验因器官分配政策变化提前关闭,结果需谨慎解读。
核心结论
- 在超米兰标准肝细胞癌有效且持续降期后,肝移植较非移植治疗改善肿瘤无事件生存和总生存。
- 降期后肿瘤缓解可能有助于扩大肝细胞癌移植标准。
研究设计与样本
- 开放标签、多中心、随机对照2b/3期试验,在意大利9个三级医疗和移植中心进行。
- 纳入18-65岁、超米兰标准、无大血管侵犯或肝外转移、5年估计移植后生存至少50%、Child-Pugh A-B7的肝细胞癌患者。
- 患者接受局部、手术或系统治疗降期,观察3个月后部分或完全缓解者按1:1随机分配至肝移植组或非移植治疗组。
- 共74例入组,29例随机前退出,45例随机:移植组23例,对照组22例。
- 主要终点:2b期为5年肿瘤无事件生存,3期为总生存;意向性分析。
主要发现
- 中位降期持续时间6个月(IQR 4-11),中位随访71个月(IQR 60-85)。
- 移植组最常见3-4级严重不良事件为丙型肝炎病毒复发(3/23,13%)和急性移植排斥(2/23,9%);对照组为栓塞后综合征(2/22,9%)。
- 治疗相关死亡4例:移植组2例(8%,心肌梗死和多器官衰竭),对照组2例(9%,肝失代偿)。
临床怎么用
- 对超米兰标准但无大血管侵犯或肝外转移、肝功能尚可的肝细胞癌,可经多学科决策行降期治疗。
- 降期后达到部分或完全缓解者,肝移植可显著改善长期肿瘤无事件生存和总生存。
- 降期后肿瘤缓解可作为扩大肝移植候选标准的参考依据。
局限性
- 试验因器官分配政策变化提前关闭,患者招募限制为4年,结果需谨慎解读。
- 样本量小(随机45例),事件数有限,置信区间较宽。
- 开放标签设计,对照组治疗为非移植的局部和系统治疗序贯。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. METHODS: We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503. FINDINGS: Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76·8% (95% CI 60·8-96·9) in the transplantation group versus 18·3% (7·1-47·0) in the control group (hazard ratio [HR] 0·20, 95% CI 0·07-0·57; p=0·003). 5-year overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation). INTERPRETATION: Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria. FUNDING: Italian Ministry of Health.
引用
- Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020. PMID: 32615109. doi:10.1016/S1470-2045(20)30224-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。